In addition, this study was performed in an era when the hemodynamic and renal effects of SGLT-2 inhibitors were not widely known and this might have influenced discontinuation rates with this agent in patients without CKD who were thought to develop acute kidney injury when exposed to empagliflozin. Here, SLC5A2 is linked to chronic kidney disease.